Julie R. Gralow, MD | Authors


Comparing Toxicities and Patient-Stated Preference in the SWOG S0307 Trial

June 03, 2014

Julie R. Gralow, MD, discusses an analysis of the phase III SWOG S0307 trial comparing toxicities and patient-stated preference for oral versus intravenous delivery of bisphosphonates as adjuvant therapy in primary breast cancer.